Mabwell (688062.SH), an innovative biopharmaceutical company with an integrated industry chain, announced that it has completed the first commercial shipment of its Denosumab Injection to the overseas ...
Privately owned, standalone infusion centers are providing an alternative to hospitals and doctors' offices for patients with ...
In another first, Sandoz launched in November 2025 the first FDA-approved biosimilar of Tysabri (natalizumab). Tyruko (natalizumab-sztn) is used to treat adult patients with relapsing multiple ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback